Affinity Maturation

About Us

Fusion Antibodies delivers new technology and innovation throughout early-stage antibody discovery. As a drug discovery and research partner, our scientists increase the pace to the clinic by guiding clients to develop the best antibodies possible. From ideation through the early stages of drug discovery, we enable biotechnology and pharmaceutical organizations towards their end-goal – the provision of treatments that improve the lives of patients throughout the world. 

Fusion Antibodies expertise is defined by our experience. Our tailored consultancy begins with the end in mind, helping clients solve complex problems.  Our approach to projects considers long-term impacts on safety, efficacy and manufacturability at all stages. As an independent team, we maximize resources by offering the flexibility and agility that antibody discovery and development programs require. This approach de-risks your program and maximizes success of your molecule to the next stage. 

Why choose Fusion Antibodies?

  • Long established (2001) UK company
  • Milestoned payments
  • Customer focused
  • Quality is paramount
  • Complete range of antibody services available
  • Competitive pricing
  • Provide a range of ancillary services through our partners
  • Project management
  • Regulatory support
  • cGMP manufacturing
  • Quality assurance and risk free delivery
Antibody engineering and humanization services
Fusion Antibodies offer as a service the humanization of monoclonal antibodies. Contact us to find out more about what Humanization can do for your therapeutic targets.
No-success no-fee guaranteed antibody sequencing service
We are so confident in our Antibody sequencing services, we offer a no-success no-fee guarantee.
Custom expression and purification of recombinant proteins
We are experts at the expression and purification of recombinant proteins from both E. coli and mammalian vectors. We specialize in protein purification using a range of techniques, including purification of insoluble proteins from inclusion bodies.

Cell line development
High yield stable cell lines for biosimilars and recombinant protein expression.

Fusion Antibodies